Mavyret and Venetoclax

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. Administration of venetoclax with a single dose of rifampin, a P-gp inhibitor when given acutely, increased venetoclax Cmax by 106% and AUC by 78%. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia. MANAGEMENT: Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor. References "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0

GENERALLY AVOID: Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. Administration of venetoclax with a single dose of rifampin, a P-gp inhibitor when given acutely, increased venetoclax Cmax by 106% and AUC by 78%. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.

MANAGEMENT: Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.

Mavyret

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: n.a.

What is Mavyret?

Venetoclax

Generic Name: venetoclax

Brand name: Venclexta, Venclexta Starting Pack

Synonyms: n.a.

What is Venetoclax?